Whilst there are currently no agents in CLL clinical trials to target NOTCH1 and SF3B1, they are clearly promising targets and a number of agents targeting these genes and pathways are under development [101, 102]. The gene discussed is NOTCH1; the disease is B-cell chronic lymphocytic leukemia.